CLIMB BIO, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
CLIMB BIO, INC. (CLYM) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $52.75 million as of 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2026-03-05
- 2024-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $52.75M.
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $52.75M.
- 2024-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $52.75M.
- 2024-06-27: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $52.75M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2024-12-31 | $52.75M 10-K · filed 2025-03-25 |
| 2024-09-30 | $52.75M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $52.75M 10-Q · filed 2024-08-14 |
| 2024-06-27 | $52.75M 10-K · filed 2026-03-05 |
| 2021-12-31 | -$694.00K 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |